First-pass extracted concept

lipid nanoparticles

Candidate: concept label8 source documents10 linked claims

Jump to explainers Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Aliases

lipid-based nanoparticle formulations, lipid nanoparticle, lipid nanoparticles, LNP, LNPs

Extracted Explainers

What the tool is doing

LNPs are delivery vehicles for therapeutic substances, especially nucleic acid vaccines and gene therapies.

Source 6DOI PubMed

Resources required

Use requires nanoparticle formulation, including components such as PEGylated lipids discussed in the abstract.

Source 6DOI PubMed

What problem it solves

They provide a vehicle for delivering therapeutic cargo.

Source 6DOI PubMed

Alternatives

The abstract does not name non-LNP delivery alternatives.

Source 6DOI PubMed

Evidence Snippets

FNP has been adopted in industrial and clinical settings-for instance, in the scalable production of lipid nanoparticles (LNPs) for mRNA-based vaccines and other nucleic acid therapeutics-demonstrating its translational potential.

Evidence 1Source 1DOI PubMedprovenance

Notably, bibliometric analysis revealed that besides metal-based nanoparticles, viral-like particles, polymer nanoparticles, and lipid nanoparticles in the field of delivery system research...

Evidence 2Source 2DOI PubMedprovenance

This review focuses on current in vivo CAR-T delivery strategies, including viral vectors ... and non-viral systems (such as lipid nanoparticles and polymer-based carriers)...

Evidence 3Source 3DOI PubMedprovenance

guide the development of safer and more targeted lipid nanoparticles

Evidence 4Source 4DOI PubMedprovenance

Using two delivery approaches-lentiviral vectors and lipid nanoparticles (LNPs)-we generated FAP-CAR-engineered Jurkat cells as a preliminary screening model

Evidence 5Source 5DOI PubMedprovenance

Lipid nanoparticles (LNPs) have become significant vehicles in the delivery of therapeutic substances, particularly for nucleic acid vaccines and gene therapies.

Evidence 6Source 6DOI PubMedprovenance

The review highlights recurring themes including lipid/polymer nanoparticles.

Evidence 7Source 7DOI PubMedprovenance

This review synthesises key advances in MD simulations and AI for two leading nanoparticle platforms (gold and lipid nanoparticles)

Evidence 8Source 8DOI PubMedprovenance

Supporting Sources

Source 1primary paper2026MEDDOI PubMed

1 evidence snippet 1 linked claim Claim 1

Source 2primary paper2026MEDDOI PubMed

1 evidence snippet 3 linked claims Claim 1 Claim 2 Claim 3

Source 3primary paper2026MEDDOI PubMed

1 evidence snippet 1 linked claim Claim 1

Source 4primary paper2025MEDDOI PubMed

1 evidence snippet 0 linked claims

Source 5primary paper2025MEDDOI PubMed

1 evidence snippet 1 linked claim Claim 1

Source 6primary paper2025MEDDOI PubMed

1 evidence snippet 2 linked claims Claim 1 Claim 2

Source 7review2025MEDDOI PubMed

1 evidence snippet 1 linked claim Claim 1

Source 8primary paper2025MEDDOI PubMed

1 evidence snippet 1 linked claim Claim 1

Linked Claims

Claim 1conclusionsupports2026Source 2DOI PubMed

Research on nanoparticles in influenza is rapidly advancing with a primary focus on vaccine development and delivery optimization.

Claim 2design objectivesupports2026Source 3DOI PubMed

Current in vivo CAR-T delivery platforms are engineered to achieve efficient, specific, and safe CAR transgene transfer.

Claim 3research prioritysupports2026Source 2DOI PubMed

Optimizing delivery systems and advancing vaccine development are central research priorities in nanoparticle influenza research.

Claim 4translational usesupports2026Source 1DOI PubMed

Flash nanoprecipitation has been adopted in industrial and clinical settings, including scalable production of lipid nanoparticles for mRNA-based vaccines and other nucleic acid therapeutics.

Claim 5trendsupports2026Source 2DOI PubMed

Metal-based nanoparticles, viral-like particles, polymer nanoparticles, and lipid nanoparticles are prominent nanoparticle classes in influenza delivery-system research.

Claim 6delivery approachsupports2025Source 5DOI PubMed

The study used lentiviral vectors and lipid nanoparticles to generate FAP-CAR-engineered Jurkat cells as a preliminary screening model.

Quoted textsource-backed

Using two delivery approaches-lentiviral vectors and lipid nanoparticles (LNPs)-we generated FAP-CAR-engineered Jurkat cells as a preliminary screening model

Claim 7predictionsupports2025Source 8DOI PubMed

AI-driven models accelerate discovery of lipid-based nanoparticle formulations by analyzing large chemical datasets and predicting optimal structures for gene delivery and vaccine development.

Claim 8role in deliverysupports2025Source 6DOI PubMed

Lipid nanoparticles are significant delivery vehicles for therapeutic substances, particularly nucleic acid vaccines and gene therapies.

Claim 9structure function relationshipsupports2025Source 6DOI PubMed

PEG chain arrangement on the nanoparticle surface and variation in PEG surface density or PEG chemistry affect LNP physicochemical properties.

Claim 10theme summarysupports2025Source 7DOI PubMed

Recurring themes in the review include lipid and polymer nanoparticles, CD20-directed targeting, pH-responsive delivery, theranostics, biomimetic systems, and emerging in vivo CAR-T and AI-guided nanomedicine directions.